Categories
Change Password!
Reset Password!
A descriptive cross-sectional study was carried out for assessing the prevalence of SARS-CoV-2-related symptoms and COVID-19 real-time polymerase chain reaction (RT-PCR) positivity in urticaria patients regarding age, sex, presence of other comorbidities, disease duration, treatment duration, and kind of therapy administered for urticaria.
Omalizumab therapy does not appear
to elevate the risk of coronavirus infection and can be safely used in people
with chronic spontaneous urticaria.
A descriptive cross-sectional study
was carried out for assessing the prevalence of SARS-CoV-2-related symptoms and
COVID-19 real-time polymerase chain reaction (RT-PCR) positivity in urticaria
patients regarding age, sex, presence of other comorbidities, disease duration,
treatment duration, and kind of therapy administered for urticaria.
The study recruited 233 participants (160 females, 73 males, mean age 44.76 ± 14.16 years) having urticaria. Participants were segregated to receive only omalizumab, only oral antihistamines, and omalizumab along with oral antihistamines.
With the aid of a telephone survey; demographical data, therapy given for
urticaria, presence of coronavirus-linked symptoms, history of close contact
with a coronavirus-infected person, and COVID-19 RT-PCR results were assessed
and verified from the medical data records.
Notably, 125/233 participants were
found to have symptoms linked with COVID-19 infection. RT-PCR testing was
carried out in 156 participants. Of 156 people with the RT-PCR test, 15 people
were reported to be positive.
In patients diagnosed with chronic
spontaneous urticaria, no profound association was witnessed between SARS-CoV-2
RT-PCR positivity and the kind of therapy given for chronic spontaneous
urticaria. Omalizumab appears to be safe in the era of coronavirus disease.
Journal of Cosmetic Dermatology
The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study
Ecem Bostan et al.
Comments (0)